Preparing For A Pricing Shift: Roche Admits Cost Is An Issue In Oncology And Beyond

Pricing by indication could be one approach to the growing problem of the cost of oncology drugs, Roche Pharmaceuticals Chief Operating Officer Pascal Soriot suggested at the firm's analyst event at the recent American Society of Clinical Oncology annual meeting.